Transplantation: Toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides

Current Opinion in Investigational Drugs

Volumn 4, Issue 11, 2003, Pages 1287-1296

  Serkova, Natalie ^a   Christians, Uwe ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Calcineurin inhibitors; Energy metabolism; Everolimus; Magnetic resonance spectroscopy; Metabonomics; Mitochondrial dysfunction; Sirolimus

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ASPARTIC ACID; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CALCIUM; CYCLOSPORIN; ENDOTHELIN 1; EVEROLIMUS; GLUTAMIC ACID; HYPOTAURINE; IMMUNOSUPPRESSIVE AGENT; INOSITOL; MACROLIDE; N ACETYLASPARTIC ACID; NEUROTRANSMITTER; NITRIC OXIDE; NUCLEOSIDE TRIPHOSPHATE; PHOSPHATE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; TACROLIMUS; TARGET OF RAPAMYCIN KINASE; TAURINE; TOCOPHEROL; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; BIOCHEMISTRY; BRAIN TOXICITY; CARDIOVASCULAR DISEASE; CELL ENERGY; CELL METABOLISM; CEREBRAL BLINDNESS; CHRONIC TOXICITY; CLINICAL TRIAL; DEMENTIA; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; GRAFT SURVIVAL; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY ALLOGRAFT REJECTION; LACTIC ACIDOSIS; LEUKOPENIA; LYMPHOMA; MELAS SYNDROME; MERRF SYNDROME; MONOTHERAPY; MUSCLE WEAKNESS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORGAN TRANSPLANTATION; PARESTHESIA; REVIEW; SEIZURE; THROMBOCYTOPENIA; TOXICOKINETICS; TREMOR; VASCULAR DISEASE;

ANIMALS; CALCINEURIN; CYCLOSPORINE; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KINETICS; MACROLIDES; ORGAN TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 0345832398     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Helderman JH, Bennett WM, Cibrik DM, Kaufman DB, Klein A, Takemoto SK: Immunosuppression: Practice and trends. Am J Transplant (2003) 3(Suppl 4):41-52. This review summarizes the history and latest trends in the management of immunosuppressive drug regimens after solid organ transplantation, based on the latest annual report of the Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients Database.
2. Campistol JM, Grinyo JM: Exploring treatment options in renal transplantation: The problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation (2001) 71(11 Suppl):SS42-SS51.
3. Hariharan S: Long-term kidney transplant survival. Am J Kidney Dis (2001) 38(6 Suppl 6):S44-S50.
4. Gonin JM: Maintenance immunosuppression: New agents and persistent dilemmas. Adv Ren Replace Ther (2000) 7(2):95-116.
5. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL: Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of microemulsion-based formulation (neoral) in organ transplantation. Drugs (2001) 61(13):1957-2016.
6. Kahan BD: Emerging strategies for the clinical application of rapamycin. Clin Biochem (1998) 31(5):341-344.
7. Kahan BD: Potential therapeutic interventions to avoid or treat chronic allograft dysfunction. Transplantation (2001) 71(11 Suppl):SS52-SS57. This article reviews the clinical potential and mechanistic aspects of combining Cl and mTOR inhibitors, and discusses the hypothesis that mTOR inhibitors may constitute an important prophylaxis against chronic allograft dysfunction.
8. Kahan BD: Cyclosporine. N Engl J Med (1989) 321(25):1725-1738.
9. De Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RAF: Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med (1987) 317(14):861-866.
10. Hauben M: Cyclosporine neurotoxicity. Pharmacotherapy (1996) 16(4):576-583.
11. Bechstein WO: Neurotoxicity of calcineurin inhibitors: Impact and clinical management. Transplant Int (2000) 13(5):313-326.
12. Gijtenbeek JM, Van Den Bent MJ, Vecht CJ: Cyclosporine neurotoxicity: A review. J Neurol (1999) 246(5):339-346.
13. Paul LC, Häryry P, Foegh M, Dennis MJ, Mihatsch MJ, Larsson E, Fellstrom B: Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: Joint proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. Transplant Proc (1993) 25(2):2022-2023.
14. De Mattos AM, Olyaei AJ, Bennett WM: Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis (2000) 35(2):333-346.
15. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB: Strategies to improve long-term outcomes after renal transplantation. N Engl J Med (2002) 346(8):580-590.
16. Lo A, Alloway RR: Strategies to reduce toxicities and improve outcomes in renal transplant recipients. Pharmacotherapy (2002) 22(3):316-328.
17. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC et al.: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation (2000) 69(7):1252-1260.
18. Vanrenterghem YF: Tailoring immunosuppressive therapy for renal transplant recipients. Pediatr Transplant (2001) 5(6):467-472.
19. Gaston RS: Maintenance immunosuppression in the renal transplant recipient: An overview. Am J Kidney Dis (2001) 38(6 Suppl 6):S25-S35.
20. Ettenger RB, Grimm EM: Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis (2001) 38(4 Suppl 2):S22-S28.
21. Bäckman L, Morales JM: Is non-nephrotoxic immunosuppression a possibility? Transplantation (2000) 69(12):SS27-30.
22. MacDonald AS: Management strategies of nephrotoxicity. Transplantation (2000) 69(12 Suppl):SS31-SS36.
23. MacDonald AS: Improving tolerability of immunosuppressive regimens. Transplantation (2001) 72(12 Suppl):S105-S112.
24. Ruiz JC, Campistol JM, Mota A, Prats D, Gutierrez A, Castro A, Pinto JR, Morales JM, Grinyo JM, Arias M: Early cyclosporine A withdrawal in kidney transplant recipients under a sirolimus-based immunosuppressive regimen: Pathological study of graft biopsies at 1-year post-transplant. Transplant Proc (2002) 34(1):92-93.
25. Snell GI, Levvey BJ, Chin W, Kotsimbos T, Whitford H, Waters KN, Richardson M, Williams TJ: Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant (2002) 21(5):540-546.
26. McKane W, Kanganas C, Preston R, Cairns T, Hakim N, Palmer A, Taube D: Treatment of calcineurin inhibitor toxicity by dose reduction plus introduction of mycophenolate mofetil. Transplant Proc (2001) 33(1-2):1224-1225.
27. Velosa JA, Larson TS, Gloor JM, Stegall MD: Cyclosporine elimination in the presence of TOR inhibitors: Effects on renal function, acute rejection and safety. Am J Kidney Dis (2001) 38(4 Suppl 2):S3-S10.
28. Schlitt HJ, Barkmann A, Böker KH, Schmidt HH, Emmanouilidis N, Rosenau J, Bahr MJ, Tusch G, Manns MP, Nashan B, Klempnauer J: Replacement of calcineurin inhibitors with mycophelate mofetil in liver-transplant patients with renal dysfunction: A randomized controlled study. Lancet (2001) 357(9256):587-591.
29. Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation (2001) 72(5):777-786.
30. Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, Lang P, Tourane JL, Claesson K, Campistol JM, Durand D, Wrammer L et al: Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation (1999) 67(7):1036-1042.
31. Neuhaus P, Klupp J, Lanrgrehr JM: mTOR inhibitors: An overview. Liver Transplant (2001) 7(6):473-484.
32. Kahan BD: The synergistic effect of cyclosporine and sirolimus. Transplantation (1997) 63(1):170.
33. Ingle GR, Sievers TM, Holt CD: Sirolimus: Continuing the evolution of transplant immunosuppression. Ann Pharmacother (2000) 34(9):1044-1055.
34. Vasquez EM: Sirolimus: A new agent for prevention of renal allograft rejection. Am J Health Syst Pharm (2000) 57(5):437-451.
35. Schuurman HJ, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R, Tanner M, Zenke G, Schuler W: SDZ-RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation (1997) 64(1):32-35.
36. Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C, Everolimus Phase 2 Study Group: Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther (2001) 69(1):48-56.
37. Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J, Vitko S, Boger R, Rordorf C: Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range. Transplantation (2002) 73(6):920-925.
38. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet (2000) 356(9255):194-202.
39. Nashan B: Early clinical experience with a novel rapamycin derivative. Ther Drug Monit (2002) 24(1):53-58.
40. Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS: RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection. Transplantation (2001) 71(10):1400-1406.
41. MacDonald AS, Rapamune Global Study Group: A worldwide, phase III, randomized, controlled, safety and efficacy study og sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation (2001) 71(2):271-280.
42. Gummert JF, Ikonen T, Morris RE: Newer immunosuppressive drugs: A review. J Am Soc Nephrol (1999) 10(6):1366-1380.
43. Plosker GL, Foster RH: Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs (2000) 59(2):323-389.
44. Winkler M, Christians U: A risk-benefit assessment of tacrolimus in transplantation. Drug Saf (1995) 12(5):348-357.
45. Hamilton GS, Steiner JP: Immunophilins: Beyond immunosuppression. J Med Chem (1998) 41(26):5119-5143.
46. Sanders CE, Curtis JJ: Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl (1995) 52:S43-S47.
47. Simonson MS, Robinson AV, Schulak JA, Hricik DE: Inhibition of endothelin-1 improves survival and vasculopathy in rat cardiac transplants treated with cyclosporine. Transplantation (2002) 73(7):1054-1059. The results of this study in heart transplant rats suggest that endothelin converting enzyme inhibition antagonizes cyclosporine toxicity, resulting in improved transplant organ function and survival.
48. Olyaei AJ, de Mattos AM, Bennett WM: Nephrotoxicity of immunosuppressive drugs: New insights and preventive strategies. Curr Opin Crit Care (2001) 7(6):384-389. This review summarizes that mechanisms of CI toxicity and their implications for transplant patient management.
49. Campistol JM, Sacks SH: Mechanisms of nephrotoxicity. Transplantation (2000) 69(Suppl 12):SS5-SS10.
50. Allison AC: Immunosuppressive drugs: The first 50 years and a glance forward. Immunopharmacology (2000) 47(2-3):63-83.
51. Vaziri ND, Ni Z, Zhang YP, Ruzics EP, Maleki P, Ding Y: Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension. Kidney Int (1998) 54(2):482-491.
52. Baud L, Ardaillou R: Involvement of reactive oxygen species in kidney damage. Br Med Bull (1993) 49(3):621-629.
53. Krauskopf A, Buetler TM, Nguyen NS, Mace K, Ruegg UT: Cyclosporin A-induced free radical generation is not mediated by cytochrome P-450. Br J Pharmacol (2002) 135(4):977-986.
54. Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, Ruegg UT: Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int (1999) 55(6):2407-2414.
55. Mason J: The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr Nephrol (1990) 4(5):554-574.
56. Nicholson JK, Wilson ID: Opinion: Understanding 'global' systems biology: Metabonomics and the continuum of metabolism. Nat Rev Drug Discov (2003) 2(8):668-676. This review discusses metabonomics-based approaches to mechanistically correlate genetic variation, disease processes and drug toxicity.
57. 13C-NMR spectroscopy. Anticancer Res (1996) 16(3B):1317-1324. An overview discussing the potential of MRS to evaluate cell biochemistry and screen for metabolic changes.
58. Serkova N, Brand A, Christians U, Leibfritz D: Evaluation of the effects of immunosuppressants on neuronal and glial cells in vitro by multinuclear magnetic resonance spectroscopy. Biochim Biophys Acta (1996) 1314(1-2):93-104.
59. Serkova N, Litt L, James TL, Sadee W, Leibfritz D, Benet LZ, Christians U: Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy. J Pharmacol Exp Ther (1999) 289(2):800-806. This study indicates that the metabolic pathway most sensitive to cyclosporine is high-energy phosphate metabolism, and that sirolimus synergistically enhances these negative effects of cyclosporine.
60. Oellerich M, Amstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, Lindholm A, Halloran P, Gallicano K, Wonigeit K, Schütz E et al: Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel. Ther Drug Monit (1995) 17(6):642-654.
61. Serkova N, Litt L, Leibfritz D, Hausen B, Morris RE, James TL, Benet LZ, Christians U: The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. Br J Pharmacol (2000) 129(3):485-492.
62. Serkova N, Donohoe P, Gottschalk S, Hainz C, Niemann CU, Bickler PE, Litt L, Benet LZ, Leibfritz D, Christians U: Comparison of the effects of cyclosporin A on the metabolism of perfused rat brain slices during normoxia and hypoxia. J Cereb Blood Flow Metab (2002) 22(3):342-352. This study demonstrates that the neuroprotective or neurotoxic nature of the effects of cyclosporine depends on both the cyclosporine and oxygen concentrations. The results also imply that cyclosporine-induced neurotoxicity and neuroprotection during hypoxia/reperfusion may both be caused by inhibition of calcium traffic through the mitochondrial membrane.
63. Serkova N, Jacobsen W, Niemann CU, Litt L, Benet LZ, Leibfritz D, Christians U: Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol (2001) 133(6):875-878. This study demonstrates that cyclosporine inhibits the Krebs cycle and mitochondrial oxidative phosphorylation in vivo. While co-administration of sirolimus enhances the negative effects of cyclosporine, co-administration of the same dose of everolimus antagonizes them.
64. Beal MF: Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta (1998) 1366(1-2):211-223.
65. Moroni I, Bugiani M, Bizzi A, Castelli G, Lamantea E, Uziel G: Cerebral white matter involvement in children with mitochondrial encephalopathies. Neuropediatrics (2002) 33(2):79-85.
66. Sengers RCA, Stadhouders AM, Trijbels JMF: Mitochondrial myopathies. Clinical, morphological and biochemical aspects. Eur J Pediatr (1984) 141(4):192-207.
67. Berenbaum MC: A method for testing for synergy with any number of agents. J Infect Dis (1978) 137(2):122-130.
68. Christians U, Serkova N: Interactions and toxicity of calcineurin inhibitors and TOR inhibitors. XIX International Congress of the Transplantation Society (2002).
69. Christians U, Gottschalk S, Hainz C, Miljus J, Benet LZ, Leibfritz D, Serkova N: Alterations in glucose metabolism by cyclosporine link to oxidative stress in rat brain slices: Interactions with mTOR inhibitors. Br J Pharmacol (2003):manuscript submitted.
70. Massicot F, Martin C, Dutertre-Catella H, Ellouk-Achard S, Pham-Huy C, Thevenin M, Rucay P, Warnet J-M, Claude J-R: Modulation of energy status and cytotoxicity induced by FK506 and cyclosporin A in a renal epithelial cell line. Arch Toxicol (1997) 71(8):529-531.
71. Salducci MD, Chauvet-Monges AM, Tillement JP, Albengres E, Testa B, Carrupt P, Crevat A: Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. J Pharmacol Exp Ther (1996) 277(1):417-422. This study demonstrates that application of cyclosporine to rat liver mitochondria in contact with calcium induced both an accumulation of calcium and a decrease in oxidative phosphorylation. The interaction of cyclosporine with mitochondrial calcium fluxes is probably the first event that triggers all the metabolic changes described in this review.
72. Wang C, Salahudeen AK: Cyclosporine nephrotoxicity: Attenuation by an antioxidant-inhibitor of lipid peroxidation in vitro and in vivo. Transplantation (1994) 58(8):940-946.
73. Buetler TM, Cottet-Maire F, Krauskopf A, Ruegg UT: Does cyclosporine A generate free radicals? Trends Pharmacol Sci (2000) 21(8):288-290. A critical review discussing the current evidence for cyclosporine-mediated reactive oxygen intermediate generation and its possible sources.
74. Su Q, Weber L, Le Hir M, Zenke G, Ryffel B: Nephrotoxicity of cyclosporine A and FK506: Inhibition of calcineurin phosphatase. Renal Physiol Biochem (1995) 18(3):128-139.
75. Serkova N, Klawitter J, Niemann CU: Organ-specific response to inhibition of mitochondrial metabolism by cyclosporine in the rat. Transplant Int (2003) 16(10):748-756. This study demonstrates that treatment of Wistar rats with cyclosporine (10 mg/kg/day for 6 days) negatively affected mitochondrial metabolism in all organs, although the metabolic responses were different, with the kidney being one of the most sensitive organs and the liver being the least sensitive.
76. Serkova NJ, Christians U: Magnetic resonance spectroscopy as a tool to identify mechanisms of immunosuppressant toxicity. Toxicologist (2003) 72(Suppl 1):3.
77. Wang H, Joseph JA: Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radical Biol Med (1999) 27(5-6):612-616.